Canadà - anglès - Health Canada

teva canada limited - ranibizumab - solution - 10mg - ranibizumab 10mg

Canadà - anglès - Health Canada

novartis pharmaceuticals canada inc - ranibizumab - solution - 10mg - ranibizumab 10mg - eent drugs, miscellaneous

Canadà - anglès - Health Canada

novartis pharmaceuticals canada inc - ranibizumab - solution - 10mg - ranibizumab 10mg - eent drugs, miscellaneous

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

samsung bioepis nz limited - ranibizumab 10 mg/ml - solution for injection - 10 mg/ml - active: ranibizumab 10 mg/ml excipient: histidine histidine hydrochloride monohydrate polysorbate 20 trehalose dihydrate water for injection - byooviz is indicated for: - the treatment of neovascular (wet) age-related macular degeneration (amd), - the treatment of visual impairment due to diabetic macular oedema (dme), - treatment of proliferative diabetic retinopathy (pdr), - the treatment of visual impairment due to choroidal neovascularisation (cnv), - the treatment of visual impairment due to choroidal neovascularisation (cnv) secondary to pathologic myopia (pm), - the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo).

Canadà - anglès - Health Canada

hoffmann-la roche limited - ranibizumab - solution - 100mg - ranibizumab 100mg

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

samsung bioepis au pty ltd - ranibizumab, quantity: 2.3 mg - injection, solution - excipient ingredients: water for injections; polysorbate 20; trehalose dihydrate; histidine hydrochloride monohydrate; histidine - byooviz (ranibizumab) is indicated in adults for:,- the treatment of neovascular (wet) age-related macular degeneration (amd),,- the treatment of visual impairment due to diabetic macular oedema (dme),,- treatment of proliferative diabetic retinopathy (pdr),,- the treatment of visual impairment due to choroidal neovascularisation (cnv),,- the treatment of visual impairment due to choroidal neovascularisation (cnv) secondary to pathologic myopia (pm),,- the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (rvo).

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

actor pharmaceuticals pty ltd - ranibizumab, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections; histidine hydrochloride monohydrate; trehalose dihydrate; polysorbate 20; histidine - raniviz (ranibizumab) is indicated in adults for:,? the treatment of neovascular (wet) age-related macular degeneration (amd),,? the treatment of visual impairment due to diabetic macular oedema (dme),,? treatment of proliferative diabetic retinopathy (pdr),,? the treatment of visual impairment due to choroidal neovascularisation,,? the treatment of visual impairment due to choroidal neovascularisation (cnv) secondary to pathologic myopia (pm),,? the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (rvo).,not recommended for use in preterm infants.

Malàisia - anglès - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - ranibizumab -

Singapur - anglès - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - ranibizumab - injection, solution - ranibizumab 1.65mg/0.165ml

Jordània - anglès - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الأدوية الأردني - the jordan drugstore co - ranibizumab 10 mg/ml - 10 mg/ml